Altimmune (STU:3G0) Change In Receivables : €1.61 Mil (TTM As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Altimmune Change In Receivables?

Altimmune's change in receivables for the quarter that ended in Dec. 2024 was €0.21 Mil. It means Altimmune's Accounts Receivable declined by €0.21 Mil from Sep. 2024 to Dec. 2024 .

Altimmune's change in receivables for the fiscal year that ended in Dec. 2024 was €1.66 Mil. It means Altimmune's Accounts Receivable declined by €1.66 Mil from Dec. 2023 to Dec. 2024 .

Altimmune's Accounts Receivable for the quarter that ended in Dec. 2024 was €0.52 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Altimmune's Days Sales Outstanding for the three months ended in Dec. 2024 was 9,490.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Altimmune's liquidation value for the three months ended in Dec. 2024 was €111.26 Mil.

Altimmune Change In Receivables Historical Data

The historical data trend for Altimmune's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Altimmune Change In Receivables Chart

Altimmune Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

-8.81

5.78

3.11

-2.12

1.66

Altimmune Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Change In Receivables	Get a 7-Day Free Trial															-0.30	2.09	-0.40	-0.30	0.21

Altimmune Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.61 Mil.

Altimmune (STU:3G0) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Altimmune's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.52	/	0.005	*	91
=	9,490.00

2. In Ben Graham's calculation of liquidation value, Altimmune's accounts receivable are only considered to be worth 75% of book value:

Altimmune's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	125.956	-	15.087	+	0.75 * 0.52	+	0.5 * 0
=	111.26

Altimmune Change In Receivables Related Terms

Thank you for viewing the detailed overview of Altimmune's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Altimmune Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Altimmune Inc (STU:3G0) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

ALT:USA 0A4C:UK 3G0:Germany

Address

910 Clopper Road, Suite 201S, Gaithersburg, MD, USA, 20878

Website

https://www.altimmune.com

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Altimmune Headlines

No Headlines